Back to search results

Weight Loss in Adults Using Semaglutide

This study is looking at how much weight adults lose when they use semaglutide, a medication for weight management, in real-world settings. It's for adults aged 18 and older who are starting semaglutide for weight management and have a Body Mass Index (BMI) of 27 or higher with a weight-related health problem, or a BMI of 30 or higher. The main goals are to see the change in body weight and how many people achieve a meaningful weight loss over 68 weeks (about 1 year and 3 months). This is an observational study, meaning researchers are just collecting information from people already using semaglutide as prescribed by their doctor. The current status of the study is unclear.

Study design
This is an observational study, meaning researchers are looking at information from people already using semaglutide. It plans to include a large number of participants, about 35,000.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' weight loss will be tracked from when they start semaglutide up to 68 weeks (about 1 year and 3 months).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07627074

Weight Loss in Adults Using Semaglutide (Real-world Study)

Recruiting
Not specifiedAges 18+Observational
Novo Nordisk A/S
~35,000 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Semaglutide

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in body weight
Measured over From index date (day 0) to week 68 (day 476)
+2 more outcomes measured

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

2 sites across 2 states
Washington1
United Kingdom1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Initiation of semaglutide for weight management during the study period.
Age more than or equal to (≥) 18 at treatment initiation
Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.

Exclusion

Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
Bariatric surgery at baseline.
Diabetes at baseline.
Pregnancy at baseline.

What this trial measures

  • Change in body weightFrom index date (day 0) to week 68 (day 476)

    Measured as kilogram (kg)

  • Change in body weightFrom index date (day 0) to week 68 (day 476)

    Measured as percentage (%)

  • Proportion of individuals achieving a clinically meaningful weight lossFrom index date (day 0) to week 68 (day 476)

    Binary (yes/no): estimated ≥5% reduction from baseline body weight